Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 621 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Brixadi Clear all
Completed Phase 2 Interventional

Alternate Day Buprenorphine Administration, Phase X - 15

NCT00000233
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
34 Years to 51 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 17, 2005 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Nalrexone Facilitated Discontinuation of Buprenorphine

NCT01895036
View directory record Official record
Conditions
Stable Opioid Dependence
Interventions
Naltrexone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 49 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Pain

NCT01298765
View directory record Official record
Conditions
Pain, Low Back Pain, Osteoarthritis, Neuropathic Pain
Interventions
BEMA Buprenorphine
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
26
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Buprenorphine for Prisoners

NCT00574067
View directory record Official record
Conditions
Heroin Addiction
Interventions
Buprenorphine +OTP, Buprenorphine +CHC, Counseling +OTP, Counseling +CHC
Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Jessup, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 22, 2026, 4:14 PM EDT
Withdrawn Phase 3 Interventional

The Safety of Using Buprenorphine With Naloxone in a Buccal Film to Initiate Treatment of Opioid Dependent Subjects

NCT02516436
View directory record Official record
Conditions
Opioid Dependence
Interventions
BEMA Buprenorphine NX, Buprenorphine
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2017
U.S. locations
3
States / cities
Birmingham, Alabama • Orem, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 22, 2026, 4:14 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

BRIDGE Device for Treatment of Opioid Withdrawal

NCT04162145
View directory record Official record
Conditions
Opioid Withdrawal, Pain, Craving
Interventions
Active BRIDGE device placement, Inactive BRIDGE device placement
Device
Lead sponsor
BrightView LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals

NCT01136356
View directory record Official record
Conditions
Opioid Abuse, Opioid Dependence
Interventions
buprenorphine, morphine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults

NCT01046539
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
RDC-0313 + Buprenorphine, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075

NCT03248947
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
buprenorphine/naloxone, Pharmacist-administered buprenorphine/naloxone maintenance care
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Not applicable Interventional Results available

OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder

NCT04948307
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
OXD01 digital therapy, Standard of Care
Device · Other
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
21
States / cities
Birmingham, Alabama • Oceanside, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 22, 2026, 4:14 PM EDT
Not yet recruiting Not applicable Interventional

Measurement-Based Care to Support Buprenorphine-Naloxone Treatment in Outpatient Addiction Clinics

NCT07839182
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Bup-MBC
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Decision Support for Opioid Use Disorders in Medical Settings: Usability Testing in an EMR

NCT03559179
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Opioid Wizard
Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bloomington, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 2 Interventional

Alternate-Day Buprenorphine Administration. Phase VIII - 9

NCT00000227
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
University of Vermont
Other
Eligibility
25 Years to 48 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 3 Interventional

Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE)

NCT05790252
View directory record Official record
Conditions
Opioid Use Disorder, Pregnancy Related, Pregnancy, High Risk, Pregnancy Complications, Buprenorphine Withdrawal
Interventions
Buprenorphine Transdermal Matrix Patch, Sham patch
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 110 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 22, 2026, 4:14 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

COVID-19-Related Opioid Treatment Policy Evaluation

NCT05028998
View directory record Official record
Conditions
Opioid-use Disorder, Alcohol Use Disorder
Interventions
Not listed
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 22, 2026, 4:14 PM EDT
Terminated Phase 4 Interventional Results available

Buprenorphine as a Treatment in Opiate Dependent Pain Patients

NCT00552578
View directory record Official record
Conditions
Opiate Addiction, Refractory Pain
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2011 · Synced Oct 22, 2026, 4:14 PM EDT
Withdrawn Phase 4 Interventional

Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine

NCT06784180
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Morphine, Bupivacaine, Fentanyl, Hydromorphone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

Alternate-Day Buprenorphine. Phase V - 6

NCT00000224
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
30 Years to 49 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders

NCT03232346
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Vivitrol, Buprenorphine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Not applicable Interventional Results available

Fostering MAT Use in Justice Populations

NCT04363320
View directory record Official record
Conditions
Opioid-use Disorder, Recidivism
Interventions
NIATx Coaching, ECHO
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 22, 2026, 4:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses

NCT07631598
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate
Interventions
Standard of Care Referral, Low Threshold Buprenorphine
Other · Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Baton Rouge, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Buprenorphine Naltrexone-P1 A-Cocaine

NCT00733720
View directory record Official record
Conditions
Cocaine-related Disorders
Interventions
Suboxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 22, 2026, 4:14 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews

NCT06354465
View directory record Official record
Conditions
Opioid Use Disorder, Criminal Justice, Treatment Adherence and Compliance
Interventions
Not listed
Lead sponsor
Lifespan
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cranston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Not applicable Interventional

Optimizing Outcomes Using Suboxone for Opiate Dependence

NCT00591617
View directory record Official record
Conditions
Opioid Dependency
Interventions
Psychosocial treatment plus Suboxone pharmacotherapy
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
15 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Oct 22, 2026, 4:14 PM EDT